Prevalence, Pathophysiology, and Management of Androgen Deficiency in Men with Metabolic Syndrome, Type 2 Diabetes Mellitus, or Both (Q38569696)

4 September 2017

Prevalence, Pathophysiology, and Management of Androgen Deficiency in Men with Metabolic Syndrome, Type 2 Diabetes Mellitus, or Both (English)

1 reference

4 September 2017

1 reference

1 reference

1 reference

Shawn Riser Taylor

1

1 reference

4 September 2017

Lindsy M Meadowcraft

series ordinal

2

1 reference

4 September 2017

Bobbie Williamson

series ordinal

3

1 reference

4 September 2017

language of work or name

English

0 references

publication date

1 August 2015

1 reference

4 September 2017

1 reference

4 September 2017

35

1 reference

4 September 2017

780-792

1 reference

4 September 2017

8

1 reference

Low testosterone levels are common and associated with insulin resistance in men with diabetes.

4 September 2017

1 reference

Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men.

21 January 2018

1 reference

Prevalence and incidence of androgen deficiency in middle-aged and older men: estimates from the Massachusetts Male Aging Study

21 January 2018

1 reference

Prevalence of hypogonadism in males aged at least 45 years: the HIM study

21 January 2018

1 reference

The 20-year public health impact and direct cost of testosterone deficiency in U.S. men.

21 January 2018

1 reference

Lower sex hormone-binding globulin is more strongly associated with metabolic syndrome than lower total testosterone in older men: the Health in Men Study

21 January 2018

1 reference

Association of testosterone and sex hormone-binding globulin with metabolic syndrome and insulin resistance in men.

21 January 2018

1 reference

Inverse association of testosterone and the metabolic syndrome in men is consistent across race and ethnic groups

21 January 2018

1 reference

Prediction of metabolic syndrome by low serum testosterone levels in men: results from the study of health in Pomerania

21 January 2018

1 reference

Metabolic syndrome, testosterone, and cardiovascular mortality in men.

21 January 2018

1 reference

Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline

21 January 2018

1 reference

Hypogonadism and diabetes

21 January 2018

1 reference

The role of obesity and type 2 diabetes mellitus in the development of male obesity-associated secondary hypogonadism

21 January 2018

1 reference

Effect of 12 months of testosterone replacement therapy on metabolic syndrome components in hypogonadal men: data from the Testim Registry in the US (TRiUS).

21 January 2018

1 reference

Low total testosterone levels are associated with the metabolic syndrome in elderly men: the role of body weight, lipids, insulin resistance, and inflammation; the Ikaria study

21 January 2018

1 reference

Sex hormone-binding globulin and risk of type 2 diabetes in women and men

21 January 2018

1 reference

Hypothalamic interleukin-1 beta and tumor necrosis factor-alpha, but not interleukin-6, mediate the endotoxin-induced suppression of the reproductive axis in rats.

21 January 2018

1 reference

Genetic evidence that raised sex hormone binding globulin (SHBG) levels reduce the risk of type 2 diabetes

21 January 2018

1 reference

Role of brain insulin receptor in control of body weight and reproduction.

21 January 2018

1 reference

Update: Hypogonadotropic hypogonadism in type 2 diabetes and obesity

21 January 2018

1 reference

Low estradiol concentrations in men with subnormal testosterone concentrations and type 2 diabetes

21 January 2018

1 reference

Prevalence of low testosterone and predisposing risk factors in men with type 1 diabetes mellitus: findings from the DCCT/EDIC

21 January 2018

1 reference

Type 1 diabetes, metabolic syndrome and cardiovascular risk

21 January 2018

1 reference

Total and free testosterone concentrations are strongly influenced by age and central obesity in men with type 1 and type 2 diabetes but correlate weakly with symptoms of androgen deficiency and diabetes-related quality of life.

21 January 2018

1 reference

Anti-pituitary antibodies and hypogonadotropic hypogonadism in type 2 diabetes: in search of a role.

21 January 2018

1 reference

Exploring the pathophysiology of hypogonadism in men with type 2 diabetes: kisspeptin-10 stimulates serum testosterone and LH secretion in men with type 2 diabetes and mild biochemical hypogonadism

21 January 2018

1 reference

Effects of five-year treatment with testosterone undecanoate on metabolic and hormonal parameters in ageing men with metabolic syndrome.

21 January 2018

1 reference

Long-term testosterone therapy in hypogonadal men ameliorates elements of the metabolic syndrome: an observational, long-term registry study

21 January 2018

1 reference

Long-term testosterone treatment in elderly men with hypogonadism and erectile dysfunction reduces obesity parameters and improves metabolic syndrome and health-related quality of life.

21 January 2018

1 reference

Treatment of hypogonadism with testosterone in patients with type 2 diabetes mellitus

21 January 2018

1 reference

Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes

21 January 2018

1 reference

Fifty-two-week treatment with diet and exercise plus transdermal testosterone reverses the metabolic syndrome and improves glycemic control in men with newly diagnosed type 2 diabetes and subnormal plasma testosterone.

21 January 2018

1 reference

Testosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome (the TIMES2 study).

21 January 2018

1 reference

Testosterone replacement therapy improves metabolic parameters in hypogonadal men with type 2 diabetes but not in men with coexisting depression: the BLAST study

21 January 2018

1 reference

Effects of long-term testosterone therapy on patients with "diabesity": results of observational studies of pooled analyses in obese hypogonadal men with type 2 diabetes

21 January 2018

1 reference

Hypogonadal obese men with and without diabetes mellitus type 2 lose weight and show improvement in cardiovascular risk factors when treated with testosterone: an observational study.

21 January 2018

1 reference

Metabolic effects of testosterone replacement therapy on hypogonadal men with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials

21 January 2018

1 reference

Adverse events associated with testosterone administration

21 January 2018

1 reference

Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels

21 January 2018

1 reference

Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men

21 January 2018

1 reference

Testosterone deficiency is associated with increased risk of mortality and testosterone replacement improves survival in men with type 2 diabetes

21 January 2018

1 reference

Testosterone therapy and cardiovascular events among men: a systematic review and meta-analysis of placebo-controlled randomized trials.

21 January 2018

1 reference

American association of clinical endocrinologists and american college of endocrinology - clinical practice guidelines for developing a diabetes mellitus comprehensive care plan - 2015

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/PHAR.1623

1 reference

4 September 2017

1 reference